Kodiak Sciences Inc Cash Flow Conversion Efficiency
Kodiak Sciences Inc cash flow conversion efficiency. Based on the latest financial reports, Kodiak Sciences Inc (KOD) has a cash flow conversion efficiency ratio of -0.757x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.24 Million) by net assets ($61.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kodiak Sciences Inc (2016–2025)
Cash flow conversion efficiency of Kodiak Sciences Inc from 2016 to 2025. This chart illustrates how Kodiak Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kodiak Sciences Inc (KOD) share price today for real-time trading data and today's change.
Kodiak Sciences Inc Cash Flow Conversion Ratio Explained
Kodiak Sciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kodiak Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kodiak Sciences Inc ranked by their cash flow conversion efficiency. Also see Kodiak Sciences Inc (KOD) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
-0.165x |
|
Pilbara Minerals Ltd
AU:PLS
|
0.044x |
|
Reinet Investments S.C.A
AS:REINA
|
0.036x |
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
0.094x |
|
Hyundai Rotem Co
KO:064350
|
-0.182x |
|
The People's Insurance Company (Group) of China Limited
F:PIR
|
0.071x |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
-0.943x |
|
ZALANDO SE UNSP.ADR /2
F:ZAL1
|
N/A |
Annual Cash Flow Conversion Efficiency for Kodiak Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kodiak Sciences Inc from 2016 to 2025. Review how financially flexible is Kodiak Sciences Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $157.38 Million | $-136.01 Million | -0.864x | -10.70% |
| 2024-12-31 | $150.29 Million | $-117.32 Million | -0.781x | -34.56% |
| 2023-12-31 | $265.78 Million | $-154.18 Million | -0.580x | -22.56% |
| 2022-12-31 | $436.17 Million | $-206.46 Million | -0.473x | -72.26% |
| 2021-12-31 | $663.32 Million | $-182.27 Million | -0.275x | -183.50% |
| 2020-12-31 | $860.75 Million | $-83.43 Million | -0.097x | +14.49% |
| 2019-12-31 | $345.36 Million | $-39.15 Million | -0.113x | +66.10% |
| 2018-12-31 | $86.83 Million | $-29.03 Million | -0.334x | -230.17% |
| 2017-12-31 | $-68.74 Million | $-17.66 Million | 0.257x | -34.24% |
| 2016-12-31 | $-41.08 Million | $-16.05 Million | 0.391x | -- |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more